NICE has published three updates spanning diagnostics, acute care, and oncology: conditional support for AI tools that detect bowel cancer polyps, new sepsis guidelines emphasizing tailored treatment, and the termination of a trastuzumab deruxtecan appraisal after no company evidence submission.
Synopulse’s NeuroPulse Daily tracks major movements across neurology, including new Parkinson’s diagnostics, ALS care funding, Huntington’s genetic medicine progress, AI-powered imaging clearance, breakthrough neurotechnology, and multimillion-dollar collaborations accelerating CNS drug discovery.
Valo Health has entered a collaboration with Merck KGaA, Darmstadt, Germany worth over $3 billion to accelerate AI-driven discovery of Parkinson’s disease therapies.
Minnesota applied for $1B under the federal Rural Health Transformation Program to strengthen rural hospitals, telehealth, and workforce capacity.
The DOJ has finalized a $38.5 million settlement with B. Braun’s Aesculap unit over allegations involving an early-failing knee implant that triggered false claims to Medicare and Medicaid.
Alkermes has increased its offer to acquire Avadel to $22.50 per share, valuing the deal at up to $2.37 billion.
Today’s neurology roundup highlights momentum across Alzheimer’s and ALS drug development, spinal cord injury research, intravascular imaging, and next-gen MRI technologies.
Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair
IQWiG has concluded that darolutamide offers no proven added benefit over apalutamide for metastatic hormone-sensitive prostate cancer.
CMS Sets 2026 Medicare Premiums and Deductibles as Cost Pressures Mount and Regulatory Fixes Temper Increases The Centers for Medicare & Medicaid Services (CMS) has released the 2026 Medicare Parts A and B premiums, deductibles, and income-related adjustment amounts, outlining another year of steady cost increases across the program. While the updates reflect predictable inflationary … Read more